Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zoller Labs Seeks To Bar Zantrex-3 Comparisons By NBTY

This article was originally published in The Tan Sheet

Executive Summary

Zoller Labs requests an injunction prohibiting NBTY from certain statements comparing its Nature's Bounty Xtreme Lean ZN-3 weight-loss product to Zoller's Zantrex-3 in a lawsuit filed June 27 in Salt Lake City, Utah federal court

You may also be interested in...



Zantrex-3 ephedra alternative

Ephedra-free, "super-stimulant" weight-loss supplement delivers "more than five times the weight loss" of Cytodyne's ephedra-containing Xenadrine RFA-1, Zoller Labs states in April 5 release. Salt Lake City-based Basic Research affiliate began selling Zantrex-3 in February at health food outlets including GNC and online. Labeling claims include "rapid weight loss" and "extreme energy," focus on supplement's superiority to ephedra. Zantrex-3 features proprietary blend including caffeine, guarana, kola nut and green tea; an 84-count bottle retails for $42.99...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel